Table 3.

Between and within study groups comparison over time for cardiometabolic risk factors.

Measurement		Timeline				Group		Time		Group × Time
		Baseline	3 months	6 months	12 months	Est.	p-value	Est.	p-value	Est.	p-value
SBP	Intervention	148.1 ± 19.0	130.3 ± 9.3	131.0 ± 12.4	130.3 ± 13.2	–3.247	0.36	–4.726	<0.001	–0.530	0.59
	Control	147.7 ± 20.0	NA	135.3 ± 13.2	134.3 ± 14.2
DBP	Intervention	85.6 ± 8.8	79.7 ± 6.5	80.6 ± 7.3	79.9 ± 8.2	–0.005	0.99	–0.709	0.02	–0.887	0.04
	Control	84.9 ± 9.5	NA	83.6 ± 7.8	82.7 ± 7.6
Total cholesterol	Intervention	6.4 ± 1.2	6.5 ± 1.3	6.5 ± 1.5	5.9 ± 1.1	0.660	0.01	–0.013	0.75	–0.149	0.01
	Control	5.9 ± 0.9	NA	6.2 ± 1.1	5.8 ± 1.0
HDL cholesterol	Intervention	1.5 ± 0.5	NA	NA	1.4 ± 0.5	0.053	0.56	–0.008	0.46	–0.015	0.32
	Control	1.5 ± 0.3	NA	NA	1.5 ± 0.3
LDL cholesterol	Intervention	4.2 ± 1.0	NA	NA	3.7 ± 0.9	0.308	0.15	–0.029	0.32	–0.123	0.003
	Control	4.0 ± 0.8	NA	NA	3.9 ± 1.0
Triglycerides	Intervention	1.7 ± 0.9	NA	NA	1.7 ± 0.7	0.367	0.02	–0.011	0.64	0.010	0.77
	Control	1.4 ± 0.5	NA	NA	1.3 ± 0.4
Fasting BG	Intervention	5.5 ± 0.6	5.5 ± 0.7	5.5 ± 0.6	5.6 ± 0.5	0.286	0.04	0.055	0.05	–0.023	0.54
	Control	5.2 ± 0.7	NA	5.3 ± 0.5	5.4 ± 0.6

BG blood glucose; DBP diastolic blood pressure; HDL high density lipoprotein; LDL low density lipoprotein; SBP systolic blood pressure. NA no measurements taken at time point. Values are expressed as mean (SD). Models are adjusted for sex and age.